Rob Mastromattei - Allient Chief Officer
| ALNT Stock | 25.29 0.72 2.93% |
Executive
Rob Mastromattei is Chief Officer of Allient
| Address | 495 Commerce Drive, Amherst, NY, United States, 14228 |
| Phone | 716 242 8634 |
| Web | https://www.allient.com |
Allient Management Efficiency
The company has return on total asset (ROA) of 0.0345 % which means that it generated a profit of $0.0345 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0563 %, meaning that it created $0.0563 on every $100 dollars invested by stockholders. Allient's management efficiency ratios could be used to measure how well Allient manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to 0.07 in 2024. Return On Capital Employed is likely to gain to 0.1 in 2024. At this time, Allient's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 627.4 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 5.1 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MSc MD | Centessa Pharmaceuticals PLC | 66 | |
| Steve Kerdock | Arrow Electronics | N/A | |
| Oliver Hennig | BioNTech SE | N/A | |
| Oliver Henning | BioNTech SE | N/A | |
| Sean Marett | BioNTech SE | 59 | |
| JD Esq | Centessa Pharmaceuticals PLC | N/A | |
| April Dovholuk | Centessa Pharmaceuticals PLC | N/A | |
| Sylke Maas | BioNTech SE | N/A | |
| Gerald Underwood | Regeneron Pharmaceuticals | N/A | |
| Anthony Bencivenga | Arrow Electronics | N/A | |
| Roy Aston | Paysafe | 44 | |
| John Hourigan | Arrow Electronics | N/A | |
| Christopher Woodall | Perseus Mining Limited | N/A | |
| Gretchen Zech | Arrow Electronics | 54 | |
| Melissa Lozner | Regeneron Pharmaceuticals | N/A | |
| Zach Taylor | BioNTech SE | N/A | |
| Sebastian MD | BioNTech SE | N/A | |
| Rachel McShane | Paysafe | N/A | |
| Bob McCowan | Regeneron Pharmaceuticals | N/A | |
| Patrice Gilooly | Regeneron Pharmaceuticals | N/A | |
| Richard Seidlitz | Arrow Electronics | 45 | |
Management Performance
| Return On Equity | 0.0563 | ||||
| Return On Asset | 0.0345 |
Allient Leadership Team
Elected by the shareholders, the Allient's board of directors comprises two types of representatives: Allient inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Allient. The board's role is to monitor Allient's management team and ensure that shareholders' interests are well served. Allient's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Allient's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Steve Warzala, Chief Officer | ||
| Joseph JD, Secretary | ||
| Helmut Pirthauer, VP Group | ||
| Kenneth May, VP CTO | ||
| Jackson Trostle, Corporate Controller | ||
| Rob Mastromattei, Chief Officer | ||
| Michael Leach, Senior CFO | ||
| Ashish Bendre, VP Group | ||
| Joseph Kubarek, Secretary | ||
| Alex Collichio, General Officer | ||
| Richard Warzala, CEO Chairman | ||
| James Michaud, Senior Officer |
Allient Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Allient a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0563 | ||||
| Return On Asset | 0.0345 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.06 % | ||||
| Current Valuation | 645.07 M | ||||
| Shares Outstanding | 16.85 M | ||||
| Shares Owned By Insiders | 15.70 % | ||||
| Shares Owned By Institutions | 67.70 % | ||||
| Number Of Shares Shorted | 256.68 K | ||||
| Price To Book | 1.52 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Allient Stock Analysis
When running Allient's price analysis, check to measure Allient's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allient is operating at the current time. Most of Allient's value examination focuses on studying past and present price action to predict the probability of Allient's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allient's price. Additionally, you may evaluate how the addition of Allient to your portfolios can decrease your overall portfolio volatility.